Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua
Killing rates (K) of 1–32 µg ml−1 caspofungin were determined in RPMI-1640 and in 50 % serum using time–kill methodology against three Candida krusei (MICs of all three isolates 0.25 µg ml−1 in RPMI-1640 and 2 µg ml−1 in serum) and three Candida inconspicua clinical isolates (MIC ranges 0.06–0.12 µg ml−1 in RPMI-1640 and 0.25–0.5 µg ml−1 in serum), against C. krusei ATCC 6258 and against one C. krusei isolate that was resistant to echinocandins (MIC 8 µg ml−1 in RPMI-1640 and 32 µg ml−1 in serum). In RPMI-1640, the highest mean K values were observed at 4 (−1.05 h−1) and 16 (−0.27 h−1) μg ml−1 caspofungin for C. krusei and C. inconspicua clinical isolates, respectively. In 50 % serum, mean K value ranges at 1–32 and 4–32 µg ml−1 concentrations for C. inconspicua and C. krusei were −1.12 to −1.44 and −0.42 to −0.57 h−1, respectively. While K values against C. krusei in RPMI-1640 and 50 % serum were comparable, serum significantly increased the killing rate against C. inconspicua (P<0.0003 for all tested concentrations). In a neutropenic murine model, daily caspofungin at 1, 2, 3, 5 and 15 mg kg−1 significantly decreased the fungal tissue burden of C. inconspicua in the kidneys (P<0.05–0.001). Against C. krusei, doses of 3, 5 and 15 mg kg−1 caspofungin were effective (P<0.05–0.01). All effective doses were comparably efficacious for both species. Only the highest 15 mg kg−1 caspofungin dose was effective even against the echinocandin-resistant C. krusei isolate. In 50 % serum, killing was concentration independent at effective concentrations (≥4 and ≥1 µg ml−1 for C. krusei and C. inconspicua, respectively), suggesting that the efficacy of dose escalation is questionable. These in vitro results were also supported by the murine model.
AndesD.,
DiekemaD. J.,
PfallerM. A.,
BohrmullerJ.,
MarchilloK.,
LepakA.2010; In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54:2497–2506 [View Article][PubMed]
CantónE.,
PemánJ.,
ValentínA.,
Espinel-IngroffA.,
GobernadoM.2009; In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Antimicrob Agents Chemother 53:3108–3111 [View Article][PubMed]
CantónE.,
Espinel-IngroffA.,
PemánJ.,
del CastilloL.2010; In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 54:2194–2197 [View Article][PubMed]
ChillerT.,
FarrokhshadK.,
BrummerE.,
StevensD. A.2000; Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus
. Antimicrob Agents Chemother 44:3302–3305 [View Article][PubMed]
FöldiR.,
SzilágyiJ.,
KardosG.,
BerényiR.,
KovácsR.,
MajorosL.2012a; Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology. Diagn Microbiol Infect Dis 73:338–342 [View Article][PubMed]
FöldiR.,
KovácsR.,
GesztelyiR.,
KardosG.,
BerényiR.,
JuhászB.,
SzilágyiJ.,
MózesJ.,
MajorosL.2012b; Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans
. Mycopathologia 174:311–318 [View Article][PubMed]
Garcia-EffronG. S.,
ParkS.,
PerlinD. S.2011; Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother 55:2245–2255 [View Article][PubMed]
MajorosL.,
KardosG.,
BelákÁ.,
MarázA.,
AsztalosL.,
CsánkyE.,
BartaZ.,
SzabóB.2003; Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures. J Clin Microbiol 41:5250–5253 [View Article][PubMed]
NasarA.,
RyanL.,
FreiC. R.,
CotaJ. M.,
WiederholdN. P.2013; Influence of serum and albumin on echinocandin in vitro potency and pharmacodynamics. Curr Fungal Infect Rep 7:89–95 [View Article]
PappasP. G.,
RotsteinC. M. F.,
BettsR. F.,
NucciM.,
TalwarD.,
De WaeleJ. J.,
VazquezJ. A.,
DupontB. F.,
HornD. L.other authors2007; Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883–893 [View Article][PubMed]
PappasP. G.,
KauffmanC. A.,
AndesD.,
BenjaminD. K.Jr,
CalandraT. F.,
EdwardsJ. E.Jr,
FillerS. G.,
FisherJ. F.,
KullbergB. J.other authors2009; Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535 [View Article][PubMed]
PfallerM. A.,
DiekemaD. J.2007; Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163 [View Article][PubMed]
PfallerM. A.,
DiekemaD. J.,
AndesD.,
ArendrupM. C.,
BrownS. D.,
LockhartS. R.,
MotylM.,
PerlinD. S.CLSI Subcommittee for Antifungal Testing2011; Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14:164–176 [View Article][PubMed]
PfallerM. A.,
NeofytosD.,
DiekemaD.,
AzieN.,
Meier-KriescheH. U.,
QuanS. P.,
HornD.2012; Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis 74:323–331 [View Article][PubMed]
SirohiB.,
PowlesR. L.,
ChopraR.,
RussellN.,
ByrneJ. L.,
PrenticeH. G.,
PotterM.,
KoblingerS.2006; A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 38:47–51 [View Article][PubMed]
SpreghiniE.,
OrlandoF.,
TavantiA.,
SenesiS.,
GianniniD.,
MansoE.,
BarchiesiF.2012; In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis
. J Antimicrob Chemother 67:2195–2202 [View Article][PubMed]
SzilágyiJ.,
FöldiR.,
BayeganS.,
KardosG.,
MajorosL.2012a; Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology. J Chemother 24:18–25 [View Article][PubMed]
SzilágyiJ.,
FöldiR.,
GesztelyiR.,
BayeganS.,
KardosG.,
JuhászB.,
MajorosL.2012b; Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model. Chemotherapy 58:159–164 [View Article][PubMed]
TortoranoA. M.,
PrigitanoA.,
DhoG.,
GranciniA.,
PasseraM.ECMM-FIMUA Study Group2012; Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol 61:389–393 [View Article][PubMed]
WiederholdN. P.,
NajvarL. K.,
BocanegraR.,
MolinaD.,
OlivoM.,
GraybillJ. R.2007; In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 51:1616–1620 [View Article][PubMed]
WiederholdN. P.,
NajvarL. K.,
BocanegraR. A.,
KirkpatrickW. R.,
PattersonT. F.2011; Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans
. Antimicrob Agents Chemother 55:3254–3260 [View Article][PubMed]
Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua